Astefor (Codeine,Ibuprofen)

Quick links to important sections

Astefor (Codeine,Ibuprofen)

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Astefor (Codeine,Ibuprofen)

Property Description
Active Ingredients Codeine, Ibuprofen
Form Oral tablet (e.g., film-coated)
Pharmacological Class Opioid Analgesic and Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common Use Relief of moderate acute pain
Origin Semi-synthetic (Codeine) and Synthetic (Ibuprofen)

What Type of Medicine is Astefor (Codeine, Ibuprofen)?

Astefor (Codeine, Ibuprofen) is identified as a combination analgesic, structured as a fixed-dose oral pharmaceutical product that delivers two distinct active compounds simultaneously: Codeine and Ibuprofen. This composition places it within two major pharmacological categories: the Non-Steroidal Anti-Inflammatory Drug (NSAID) class and the opioid analgesic class. The use of this specific dual formulation is clinically recognized for providing enhanced pain relief compared to its single-component counterparts, making it suitable for patients requiring more robust analgesic action than basic non-opioid options.

The Core Composition: Ibuprofen and Codeine

The efficacy of the medication relies on the synergistic effect achieved by combining its two active ingredients. Ibuprofen, a synthetic propionic acid derivative, is responsible for the peripheral actions, working to reduce the formation of chemical mediators that intensify inflammation and pain. Conversely, Codeine, a semi-synthetic derivative, contributes the central action, where it modifies the perception of pain signals. This calculated combination is supported by pharmacological studies demonstrating the formulation's utility across various acute painful states.

General Purpose and Benefit of This Combination

The general purpose of this combination product is to provide comprehensive relief for moderate pain, such as acute musculoskeletal discomfort, especially when a non-opioid analgesic alone is insufficient. The medication's dual-action architecture ensures that it simultaneously addresses the symptoms of inflammation and reduces the central intensity of the pain signals. The strategic inclusion of Ibuprofen alongside the opioid component offers a unique advantage by treating the inflammatory source of pain while also managing its central processing, making it a strong option designated for short-term treatment.

What side effects are possible with Astefor (Codeine,Ibuprofen)?

Possible Side Effects and Safety Information

The safety profile of Astefor (Codeine/Ibuprofen) is structured according to official regulatory documentation, detailing adverse reactions by frequency and the organ systems they affect. This information is critical for understanding the potential risks associated with the medicine.

Frequency-Classified Adverse Reactions

Adverse effects are categorized based on their expected occurrence:

Classification Examples of Reactions
Very Common / Common Dizziness, drowsiness, constipation, nausea, vomiting, dyspepsia, headache.
Rare Peptic ulceration, gastrointestinal perforation or haemorrhage, flatulence.
Very Rare Severe skin reactions (e.g., SJS, TEN), haematopoietic disorders, anaphylaxis, acute renal failure.

Serious Adverse Reactions and Systemic Risks

Regulatory documentation highlights several serious, though rare, adverse reactions, particularly related to the medicine’s two active components:

  • Gastrointestinal Risk: Potential for serious events such as ulceration, bleeding, and perforation of the stomach or intestines (an NSAID class effect).
  • Cardiovascular Risk: Increased risk of serious thrombotic events, including myocardial infarction and stroke (an NSAID class effect), with risk potentially increasing with duration and dose.
  • Respiratory Depression: The codeine component carries a risk of life-threatening respiratory depression.
  • Addiction and Dependence: Prolonged use of codeine may lead to tolerance, physical dependence, and addiction.

Population and Exposure Restrictions

Official labeling defines specific constraints based on patient characteristics and duration of use:

  • Pediatric Use: Use is generally contraindicated in all children under 12 years of age and in adolescents after tonsillectomy/adenoidectomy.
  • Pregnancy: Contraindicated during the third trimester of pregnancy.
  • Duration: The risks of addiction and gastrointestinal harm increase with the duration of use. The official recommendation is to use the lowest effective dose for the shortest possible duration.

Overdose and Emergency Response

Overdose and When to Seek Help

Seek immediate medical attention or call emergency services immediately if an overdose of Astefor (Codeine, Ibuprofen) is suspected. This combination presents a risk of serious toxicity from both components, as documented in official prescribing information.

Documented Overdose Manifestations

Official regulatory sources describe two primary toxicity profiles:

Toxicity Component Signs and Symptoms (Documented)
Codeine (Opioid) Life-threatening Respiratory Depression, profound CNS depression (drowsiness, coma), hypotension, and pinpoint pupils (miosis).
Ibuprofen (NSAID) Gastrointestinal effects (nausea, vomiting, bleeding), tinnitus, metabolic acidosis, and the risk of Acute Renal Failure or severe Gastrointestinal Haemorrhage.

Required Emergency Actions and Management

All suspected overdoses require urgent assessment. Management, as defined by regulatory bodies, focuses on the specific toxicities:

  • Antidote: The specific antidote, Naloxone, is used to reverse severe CNS and respiratory depression caused by the Codeine component.
  • Procedural Steps: Supportive measures, including maintenance of a clear airway and continuous monitoring of vital signs, are required. Activated Charcoal may be administered in a hospital setting for recent Ibuprofen ingestions.

Population-Specific Overdose Risk

Regulatory warnings explicitly state that accidental ingestion of even one dose can result in a fatal overdose due to the Codeine component, particularly in children. Additionally, individuals who are ultra-rapid metabolizers of Codeine are at a documented risk of life-threatening respiratory depression.

Therapeutic Uses of Astefor (Codeine,Ibuprofen)

What Astefor (Codeine,Ibuprofen) Treats: Main Uses and Benefits

This combination analgesic is specifically indicated for the short-term, symptomatic relief of moderate acute pain when supportive symptom management beyond single non-opioid options is appropriate. It addresses symptoms that are intense enough to disrupt daily stability, and provides support that helps ease the overall symptom burden.

Astefor is commonly applied in therapeutic contexts involving pain driven by acute inflammatory states and musculoskeletal discomfort, such as acute backache, muscular pain, and post-traumatic strains. The medication provides short-term symptomatic assistance for pronounced, episodic pain in conditions like severe dental pain, migraine, and painful menstrual periods (dysmenorrhoea). This is relevant for easing symptoms related to inflammatory or irritative states and may assist with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Relief for Moderate Pain This medication is commonly used to manage pain intensity classified as moderate, applicable in clinical settings that involve acute or unstable symptom patterns.

Regulatory References

  1. Therapeutic Goods Administration (TGA) in Australia

Eligibility and Restrictions for Use

Official Eligibility for Astefor (Codeine, Ibuprofen)

The regulatory profile for Codeine/Ibuprofen combination products strictly defines the patient populations permitted to use the medicine, based on constraints from both the opioid and NSAID components. Use is generally allowed for adults and adolescents 12 years of age and older for the short-term treatment of moderate acute pain when non-opioid options are insufficient.


Populations for Whom Use is Contraindicated

Use is strictly prohibited in several populations due to the risk of serious adverse reactions, as defined in official labeling:

  • Pediatric Exclusion: Children under 12 years of age and adolescents (0–18 years) following tonsillectomy/adenoidectomy for Obstructive Sleep Apnea Syndrome (OSAS).
  • Metabolic Status: Patients known to be CYP2D6 ultra-rapid metabolizers of Codeine.
  • Organ Failure: Individuals with severe hepatic, renal, or heart failure.
  • Allergy & GI Risk: Patients with a history of allergic reaction to any NSAID, or those with active or recurrent peptic ulceration or gastrointestinal bleeding.
  • Reproductive Status: Women in the last trimester of pregnancy and those who are breastfeeding.

Restricted or Conditional Use

Use requires special consideration or caution in elderly patients and those with mild-to-moderate hepatic or renal impairment. These groups may require closer monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Astefor (Codeine, Ibuprofen) is structured around potential pharmacokinetic and pharmacodynamic interactions documented in government regulatory sources. These documented interactions establish important restrictions on co-administration with other medicines and substances.

Formal Restrictions and Interaction Patterns

Classification Interacting Substance/Class Official Interaction Description/Restriction
Contraindicated Monoamine Oxidase Inhibitors (MAOIs) Strictly prohibited for co-use; a mandatory 14-day timing separation rule applies.
Contraindicated Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Co-administration is restricted due to an increased risk of serious gastrointestinal events.
Pharmacodynamic CNS Depressants and Alcohol Additive CNS depression may occur, increasing the risk of profound sedation.
Pharmacokinetic CYP2D6 Inhibitors (e.g., fluoxetine) May reduce the formation of codeine’s active metabolite, resulting in reduced analgesic effectiveness.
Pharmacokinetic CYP3A4 Inhibitors (e.g., ketoconazole) May increase exposure to codeine, potentially increasing the risk of opioid-related toxicity.
Exposure Alteration Lithium and Methotrexate Co-administration may increase the plasma concentrations of these medicines due to reduced clearance by the Ibuprofen component.

Population-Specific Interaction Notes

Codeine is formally contraindicated in children younger than 18 years post-tonsillectomy/adenoidectomy. It is also contraindicated in individuals identified as CYP2D6 ultra-rapid metabolizers due to the officially documented risk of life-threatening respiratory depression from rapid morphine conversion. Additionally, co-administration with Mifepristone requires a regulatory separation of 8–12 days.

Mechanism of Action

Dual Mechanism: Peripheral Inhibition and Central Modulation

Astefor's mechanism involves two active components targeting distinct systems: ibuprofen modulates peripheral processes by acting on enzymes, while codeine primarily influences central signaling by activating receptors. This strategy engages mechanisms that modulate prostaglandin synthesis and mu-OR activation, influencing peripheral signal generation and central transmission of nociceptive input.

The ibuprofen component achieves its action by reversibly inhibiting Cyclooxygenase (COX) enzymes. This enzyme blockade curtails the synthesis of prostaglandins, resulting in a reduction of prostaglandin-mediated sensitization of peripheral nociceptors and influences the hypothalamic thermoregulatory set point.

The codeine component acts as a prodrug, requiring metabolic conversion (via CYP2D6) to morphine, its active form. Morphine is an agonist at the mu-opioid receptor (mu-OR). Receptor activation causes neuronal hyperpolarization, which suppresses the release of excitatory neurotransmitters like Substance P, thus modulating nociceptive signal transmission and central processing.

Pharmacogenomic Constraint on Central Action

The full central mechanism is contingent upon the CYP2D6 enzyme conversion step. Due to genetic variation, the efficiency of this biotransformation differs among individuals. In those with reduced CYP2D6 function, the resulting mu-OR agonism is constrained, and the central mechanism is functionally limited.

Dosage and Administration Information

How to Use Astefor (Codeine,Ibuprofen)

Astefor is administered through the oral route as a fixed-dose combination tablet, and its usage is strictly defined by regulatory guidelines concerning dose, frequency, and duration. These guidelines establish a protocol for short-term, acute pain management.


Standard Dosing and Frequency

The standard regimen for adults and adolescents 12 years of age and older begins with an initial and subsequent dose of one to two tablets (containing 200 mg to 400 mg Ibuprofen and 12.8 mg to 25.6 mg Codeine). The dose must be taken only as necessary.

Administration is constrained by a mandatory minimum interval of four hours between doses. The total intake must not exceed a maximum of six tablets (equivalent to 1200 mg of Ibuprofen and 76.8 mg of Codeine) in any 24-hour period.


Administration Conditions and Duration

As a crucial administration principle, the tablets must be swallowed whole with fluid, and should be taken with or immediately after food or a drink of milk to minimise gastric irritation.

Treatment is strictly limited to a maximum of three consecutive days for short-term use. If pain symptoms persist or worsen beyond this duration, the course of action is to seek further medical assessment.


Population-Specific Rules

Astefor is not for use in children under 12 years of age. For older adults or patients with known renal or hepatic impairment, the official use pattern requires that the dose be assessed individually and generally kept to the lowest effective level for the shortest duration necessary.

Recent Clinical Evidence

Research Evidence / Overview of studies for Astefor (Codeine, Ibuprofen)


Evidence from Studies on Acute Postoperative Pain

Research exploring this combination was primarily conducted through short-term randomized controlled trials (RCTs) and systematic reviews. These studies focus on settings like the pain experienced by adult patients following surgical procedures, such as dental surgery. Research explored how the combination was associated with patient-reported outcomes describing perceived discomfort. Studies reported that the combination was evaluated in research exploring how pain measurements differed between participants using the combination and those using an inactive substance (placebo). Long-term effects are not fully established based on this short-term research; the results apply only to the specific populations studied, and follow-up durations were limited.


Evidence from Studies on General Moderate Acute Pain

The combination was evaluated in systematic reviews and comparison studies examining conditions associated with acute or disruptive episodes, such as acute musculoskeletal discomfort. Research explored short-term symptom changes relevant in trials assessing short-term or episodic symptom patterns. Studies reported how symptoms evolved in the observed populations, and research highlighted changes measured during the study period related to physical discomfort. Comparison studies described patterns where pain measurements were observed in a manner consistent with those seen with other combined non-opioid medications. The certainty remains low in some areas because evidence for this combination is often part of broader reviews of codeine combined with various non-opioids.


Comparison of Combination Therapy to Single Ingredients

Research describes various study designs that aim to compare the effects of the fixed-dose combination with its individual components or other standard pain relievers. Studies monitored patient-reported outcomes describing perceived discomfort, exploring how the combination was associated with symptom patterns compared to using a single ingredient. Research describes patterns related to pain metrics observed when the combination was evaluated versus the single ingredients, particularly in the initial post-operative period. Comparative evidence is lacking for extended treatment courses, and the follow-up durations were limited.


What Remains Uncertain About the Research

Evidence highlights what is known, which is primarily the short-term analgesic patterns in adults, and what is still uncertain. A key research limitation is that isolating and quantifying the additive effect of the codeine component over the ibuprofen alone is difficult to do consistently across all acute pain indications. Evidence specifically describing the study of this combination product in children remains a documented research gap, and limited information is available for outcomes in groups such as older adults.

Frequently Asked Questions (FAQ)

Common questions about Astefor (Codeine,Ibuprofen) (FAQ)


Q: Is Astefor considered a strong painkiller?

A: According to official product information, this medicine is indicated for short-term relief of acute, moderate pain. It is used when pain is not adequately controlled by basic non-opioid medicines like paracetamol or ibuprofen alone. Its use is defined by regulatory criteria that reserve it for pain not relieved by non-opioid options.


Q: What's the difference between Astefor and plain Ibuprofen?

A: This medicine is a fixed-dose combination product that adds codeine to ibuprofen. Codeine is an opioid that provides a central action, which means it works in the brain and nervous system to alter pain signals. The dual mechanism is intended to provide a combined action on pain compared to using ibuprofen alone.


Q: Why is Codeine sometimes classified as an opioid?

A: Codeine is classified as an opioid because of how it works in the body. The mechanism involves the potential for conversion to morphine, which acts on specific sites in the brain and nervous system called mu-opioid receptors. This places it in the same class of receptors targeted by morphine to produce a pain-relieving effect.


Q: Are there any common but less severe allergic reactions to Astefor?

A: Official documents note that common side effects related to hypersensitivity may include skin reactions such as urticaria (hives) and pruritus (itching). While less severe allergic responses are possible, the official safety profile also documents that severe, systemic allergic reactions (anaphylaxis) may occur, although this is rare.


Q: Does Astefor cause changes in mood or confusion?

A: Yes, the regulatory safety profile lists dizziness and drowsiness as common adverse events. Furthermore, official documentation notes that confusion, mood alteration, depression, and restlessness are among the adverse effects that have been observed with its use.


Q: What should I do if I think I'm having a serious side effect (non-directive, process-focused)?

A: According to official safety communications, if signs of a serious adverse event occur, such as difficulty breathing, chest pain, black stools, fainting, or seizures, it is necessary to seek emergency medical attention. The discontinuation of the medicine should be discussed with a healthcare provider immediately.


Q: Is Astefor the first-line treatment for any specific condition?

A: Official product indications state that this medicine is used for acute, moderate pain that has not been adequately relieved by non-opioid pain relievers alone. Therefore, it is generally intended for use after simpler medications have proven insufficient.


Q: Does Astefor interact with blood thinners or antiplatelet drugs?

A: Yes, the ibuprofen component of this medicine interacts with blood thinners (anticoagulants). Regulatory guidance specifies that close monitoring of blood clotting time (prothrombin time) is required when this medicine is used alongside anticoagulant therapy.


Q: How is Astefor different from other combination pain relievers?

A: This fixed-dose product combines an opioid (codeine) with a non-steroidal anti-inflammatory drug (ibuprofen). Its difference lies in this specific pairing, which carries its own unique profile of benefits and risks, such as the potential for gastrointestinal and renal harm.


Q: How quickly does Astefor usually start working?

A: Pharmacokinetic data indicates that the codeine component typically reaches its peak concentration in the bloodstream approximately one hour after ingestion. This peak concentration is associated with the potential for the medicine's maximum effect.


Q: How long do the effects of Astefor last?

A: The half-life for codeine is reported to be between three and four hours, and for ibuprofen, it is between 1.9 and 2.2 hours. These reported half-lives are consistent with the typical time gap between doses specified in the product's official instructions.


Q: Are there any common interactions with over-the-counter cold medicines?

A: Regulatory guidance indicates no contraindication for taking this medicine with paracetamol (acetaminophen). However, official warnings caution against taking it with other non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin or naproxen, which are sometimes found in cold medicines, due to an increased risk of side effects.


Q: Can Astefor affect my ability to drive or operate machinery?

A: Yes, official product information includes warnings regarding the ability to drive or operate machinery. Official product warnings advise against driving or engaging in activities that require alertness if side effects like drowsiness or dizziness are experienced.


Q: Is there evidence that Astefor is more effective than paracetamol/acetaminophen for certain pain?

A: Official documents indicate this medicine is reserved for pain that is not relieved by single-ingredient non-opioids, which includes paracetamol. This regulatory classification acknowledges the combination's use in situations where paracetamol alone is insufficient to control the pain.


Q: Does Astefor interact with anti-depressant medications?

A: Yes, interactions are documented with certain classes of antidepressants. Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly prohibited. Regulatory sources document that central nervous system depression or excitation is a potential risk if the medicine is taken concurrently with MAOIs or within two weeks of stopping them.


Q: What is the risk of overdose with Astefor?

A: Overdose is considered a serious medical emergency due to the risks posed by both active ingredients. The documented risks include life-threatening respiratory depression, severe bleeding in the stomach or intestines, cardiac events, and seizures.


Q: Do studies support the use of Astefor for tension headaches?

A: Yes, the list of regulatory indications for this combination medicine includes the relief of pain associated with tension headaches and migraine.


Q: What happens if I stop taking Astefor suddenly?

A: Official safety information indicates that prolonged regular use can lead to physical dependence. If physical dependence has developed, official safety information recommends that discontinuation be gradual to help avoid potential withdrawal symptoms, such as restlessness and irritability.


Q: Can Astefor affect blood pressure?

A: Yes, the official adverse event profile notes that this medicine can affect blood pressure. Both hypertension (an increase in blood pressure) and orthostatic hypotension (a drop in blood pressure when changing positions) have been reported as possible adverse events.


Q: Are there specific vitamins or supplements that interact with Astefor?

A: Regulatory documents state that information is generally lacking on the safety profile of vitamins or complementary medicines when taken with this combination, as they are not tested in the same rigorous way as prescription drugs.


Q: Why do people sometimes misuse medicines containing Codeine?

A: Regulatory reviews of this class of medicine note that misuse is connected to the codeine component and the risk of developing dependence or abuse. This misuse has been linked to severe adverse health outcomes, including damage to the kidneys and gastrointestinal system.


Q: What is the official classification of Astefor's safety?

A: As a medicine containing an opioid, it is subject to regulation under controlled substance schedules in many countries, such as Schedule III or V in the USA. Its specific regulatory status (e.g., prescription-only or over-the-counter) is subject to ongoing review by national health authorities due to concerns about the risk of abuse and dependence.


Q: Does Astefor interact with any herbal remedies?

A: Official regulatory sources state that safety information regarding the co-administration of herbal remedies with this medicine is limited, as herbal products are not subjected to the same rigorous testing as prescription drugs.


Q: Why is Astefor prescription-only in some places but not others?

A: The availability of this medicine is determined by national regulatory bodies and varies by country. For example, it is prescription-only in some regions due to the risk of abuse and dependence, but in others, it may be available over the counter, reflecting differing national assessments of the overall safety profile.


Q: What does 'Codeine phosphate' mean on the label?

A: The term 'Codeine phosphate' on the label refers to the specific salt form of the codeine component used in the tablet formulation. The use of phosphate helps ensure the stability and pharmaceutical quality of the active ingredient.

How should Astefor (Codeine,Ibuprofen) be stored and disposed of?

Storage and Disposal of Codeine/Ibuprofen Tablets

The storage and disposal instructions for Codeine/Ibuprofen tablets are officially defined to maintain product stability and ensure public safety.

Requirement Official Instruction
Storage Temperature Store below 25 C in a cool, dry place.
Environmental Protection Avoid heat and dampness; do not store in bathrooms, cars, or near a sink.
Packaging Rule Keep the medicine in the original container/pack until the time of use.
Child Safety Must be kept out of the sight and reach of children; a locked cupboard at least 1.5 metres above the ground is recommended.
Disposal Do not use after the expiry date. Unused or expired product must be returned to a pharmacist for disposal or handled via authorized drug take-back programs to safely manage the opioid component.

These instructions define the mandatory conditions for storage and disposal in line with government regulatory requirements for this combination product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Astefor (Codeine,Ibuprofen) found in:

A-Z Index: